Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
3.4
Journals
Vaccines
Special Issues
Animal Infectious Diseases and Vaccinology in One Health
share announcement

Animal Infectious Diseases and Vaccinology in One Health

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Veterinary Vaccines".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 1417

Special Issue Editors

Dr. Edith Rojas-Anaya

E-Mail Website
Guest Editor
Instituto Nacional de Investigaciones Forestales, Agricolas y Pecuarias, Tepatitlan de Morelos, Mexico
Interests: virology; molecular biology; animal health; metagenomics
Dr. Elizabeth Loza-Rubio

E-Mail Website
Guest Editor
Instituto Nacional de Investigaciones Forestales, Agricolas y Pecuarias, Santa Catarina, Mexico City, Mexico
Interests: vaccinology; animal health; one health; diagnosis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Many infectious diseases in animals cause significant damage to humankind. Exploring traditional and new solutions to mitigate these impacts is crucial. One approach involves the correct use of commercial vaccines and the implementation of new or autogenous vaccines. Additionally, where feasible, strategies can be developed to study and control diseases through understanding environmental factors and the interconnectedness of public and animal health, a concept known as “One Health”. These strategies can be valuable for various stakeholders in managing different infectious diseases. Original research articles and reviews are both welcome in this Special Issue.

Dr. Edith Rojas-Anaya
Dr. Elizabeth Loza-Rubio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccinology
  • productive animals
  • one health
  • infectious diseases
  • zoonoses

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 1056 KB  
Article
Presence of Vaccine-Induced Antibodies Against Leptospira spp. Complicates the Diagnosis of Leptospirosis by the Microscopic Agglutination Test
by Katharina Gesa Schmitt, Michèle Bergmann, Hans van der Linden, Ahmed A. Ahmed, Reinhard K. Straubinger, Yury Zablotski and Katrin Hartmann
Vaccines 2025, 13(9), 956; https://doi.org/10.3390/vaccines13090956 - 8 Sep 2025
Viewed by 182
Abstract
Background: Leptospirosis is a potentially fatal infectious disease. Therefore, annual revaccination of dogs is recommended, but this can lead to diagnostic interference due to vaccine-induced antibodies. This study determined the prevalence of Leptospira spp.-specific antibodies in 97 healthy adult dogs revaccinated with a [...] Read more.
Background: Leptospirosis is a potentially fatal infectious disease. Therefore, annual revaccination of dogs is recommended, but this can lead to diagnostic interference due to vaccine-induced antibodies. This study determined the prevalence of Leptospira spp.-specific antibodies in 97 healthy adult dogs revaccinated with a 4-serovar vaccine (Nobivac® L4). Methods: Antibodies were measured with a microscopic agglutination test against 12 serovars before (week 0) and 2, 4, 12, 26, and 52 weeks after revaccination. Logistic regression analysis was performed to determine the presence of pre-revaccination antibodies. Mixed-effect logistic regression analyses and chi-squared tests were used to compare differences between antibodies against vaccine serovars and between vaccine and non-vaccine serovars at different time points. Results: Overall, 63/97 dogs (64.9%) had antibodies against vaccine serovars before revaccination. During the study period, antibodies against ≥1 vaccine serovars were detected in all 97 dogs (100.0%). The highest likelihood of detectable antibodies was present in weeks 2 and 4, but 71/97 dogs (73.2%) had antibodies persisting 52 weeks after revaccination. Of 97 dogs, 75 dogs (78.4%) even had antibodies against ≥1 non-vaccine serovars. Among those, 19/75 (25.0%) had a fourfold titre increase. Conclusions: These findings suggest that high levels of antibody titres against Leptospira spp. occur frequently and cross-reactivity against non-vaccine serovars is likely. The detection of vaccine-induced antibodies can therefore complicate the diagnosis of leptospirosis. Full article
(This article belongs to the Special Issue Animal Infectious Diseases and Vaccinology in One Health)
►▼ Show Figures

Figure 1

35 pages, 4814 KB  
Article
FcRn-Driven Nanoengineered Mucosal Vaccine with Multi-Epitope Fusion Induces Robust Dual Immunity and Long-Term Protection Against Brucella
by Tingting Tian, Yuejie Zhu, Kaiyu Shang, Huidong Shi, Ruixue Xu, Mingzhe Li, Fuling Pu, Junyu Kuang, Jianbing Ding and Fengbo Zhang
Vaccines 2025, 13(6), 567; https://doi.org/10.3390/vaccines13060567 - 26 May 2025
Viewed by 913
Abstract
Background: Brucellosis poses a significant public health challenge, necessitating effective vaccine development. Current vaccines have limitations such as safety concerns and inadequate mucosal immunity. This study aims to develop an FcRn-targeted mucosal Brucella vaccine by fusing the human Fc domain with Brucella’s [...] Read more.
Background: Brucellosis poses a significant public health challenge, necessitating effective vaccine development. Current vaccines have limitations such as safety concerns and inadequate mucosal immunity. This study aims to develop an FcRn-targeted mucosal Brucella vaccine by fusing the human Fc domain with Brucella’s multi-epitope protein (MEV), proposing a novel approach for human brucellosis prevention. Methods: The study developed a recombinant antigen (h-tFc-MEV) through computational analyses to validate antigenicity, structural stability, solubility, and allergenic potential. Molecular simulations confirmed FcRn binding. The vaccine was delivered orally via chitosan nanoparticles in murine models. Immunization was compared to MEV-only immunization. Post-challenge assessments were conducted to evaluate protection against Brucella colonization. Mechanistic studies investigated dendritic cell activation and antigen presentation. Results: Computational analyses showed that the antigen had favorable properties without allergenic potential. Molecular simulations demonstrated robust FcRn binding. In murine models, oral delivery elicited enhanced systemic immunity with elevated serum IgG titers and amplified CD4+/CD8+ T-cell ratios compared to MEV-only immunization. Mucosal immunity was evidenced by significant IgA upregulation across multiple tracts. Long-term immune memory persisted for six months. Post-challenge assessments revealed markedly reduced Brucella colonization in visceral organs. Mechanistic studies identified FcRn-mediated dendritic cell activation through enhanced MHC-II expression and antigen presentation efficiency. Conclusions: The FcRn-targeted strategy establishes concurrent mucosal and systemic protective immunity against Brucella infection. This novel vaccine candidate shows potential for effective human brucellosis prevention, offering a promising approach to address the limitations of current vaccines. Full article
(This article belongs to the Special Issue Animal Infectious Diseases and Vaccinology in One Health)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop